Oral Wegovy regulatory filing in China supports Novo Nordisk stock at current level

Traders Union
All News
Financial News
Novo Nordisk drops 0.75% to $43.21

Highlights

Novo Nordisk faces short-term operational and regulatory risks after confirming a data breach impacting internal clinical trial IT systems.
The company seeks regulatory approval in China for its oral Wegovy weight-loss drug, aiming to expand its obesity drug presence.
Shares remain under selling pressure, trading below key moving averages, with a forecasted range of $42.1 to $44.32 and downside risk dominating.

Data breach and China ambitions reshape sentiment amid broader selloff

Novo Nordisk confirmed a data breach impacting some of its internal IT systems used in a clinical trial, introducing short-term operational and regulatory risks, according to Penligent. The company has notified relevant authorities and affected parties as part of its response process, aiming to comply with legal obligations and contain any fallout. Additionally, Novo Nordisk announced plans to seek regulatory approval in China for an oral version of its Wegovy weight-loss drug, targeting future growth in the obesity segment, reported Scandasia. These developments come as the stock faces broader selling pressure.

Bearish momentum dominates as technical barriers resist reversal

Technically, NVO is trading below the MA-20 ($43.62), MA-50 ($43.7), and the long-term MA-200 ($48.15) on the H1 chart. The Ichimoku Kijun currently stands as resistance at $43.76, and price action has remained below this level. Momentum signals show MACD in Sell mode, CCI also issuing a Sell signal, and BBP reflecting seller dominance. RSI is soft at 43.34, while Stoch RSI prints a Strong Buy, hinting at the potential for brief rebound attempts. ADX and the Awesome Oscillator are neutral, pointing to low directional conviction amid today's high volatility range.

Downside risks dominate outlook as sideways trading persists

Looking ahead, the projected range for the stock over the next few sessions is $42.1 to $44.32, representing a typical volatility band relative to current levels. The probability of upward movement is low at 25%, while sellers are favored with a 75% probability of continued weakness; the baseline scenario is continued sideways trading within this corridor. A meaningful bullish move would require a close above the $43.76 Kijun resistance, while a break below $42.1 would likely trigger further declines.

Anton Kharitonov, analyst at Traders Union, sees Novo Nordisk under pressure from both technical weakness and adverse news flow. He notes the stock is caught below all key moving averages, with momentum tilted to the downside. Near-term sentiment is dented further by the confirmed data breach, overshadowing future growth prospects in China. "Base case remains sideways-to-lower as long as price holds below $43.76; any rebound attempts face strong resistance at this level."

Previously it was reported that Novo Nordisk faced heightened operational and reputational risks following a cybersecurity incident, with analysts cautioning that technical signals pointed to ongoing downside pressure. The latest developments, including new regulatory ambitions and persistent selling momentum, reinforce a cautious stance, making it critical for investors to monitor for a decisive shift above the $43.76 resistance or a breakdown below $42.1 as cues for the next significant move.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.